Healthcare News

Nxera Pharma Submits Marketing Authorization Application for Vamorolone in South Korea for the Treatment of Duchenne Muscular Dystrophy.

PRESSRELEASE 2026-10-22 Linda Linnér utses som ny CFO för Arcoma AB i Q4 Arcoma AB har utsett Linda Linnér till ny Chief Financial Officer (CFO). Linda tillträder tjänsten under Q4. Linda har...

PRESSRELEASE 2026-10-22 Kvartalsrapport Q3 2026. Stark lönsamhet och positiv utveckling i Nordamerika (MAR) FINANSIELLT SAMMANDRAG Tredje kvartalet Nettoomsättningen för kvartalet uppgick till 26...

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective,...

Privosegtor dró úr aukningu á léttkeðju taugaþráða (e. neurofilament light chain, NfL) og trefjasúru stoðfrumupróteini (e. glial fibrillary acidic protein, GFAP) í blóðvökva eftir upphaf einkenna...

Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective,...

London, UK, 22 October 2026 - Persica Pharmaceuticals Limited (“Persica”), a clinical-stage biotechnology company developing PP353, a targeted, non-opioid treatment for vertebrogenic Lumbar Back Pain...

Pharming announces preliminary, unaudited revenue and select financial information for Q3 2026 & full results brought forward to October 27, 2026.

Continued strong VYVGART performance drives $1.7 billion in global product net sales, representing 54% year-over-year growth and 13% quarter-over-quarter growth sBLA for VYVGART Hytrulo in IMNM on...

Year-to-date total sales growth of 24.6% at CER1, or 23.0% as reported, with the core portfolio2 achieving sales growth of 24.2%1 Further upgraded FY 2026 financial guidance: total sales growth around...